Skip to main content
Erschienen in: Heart Failure Reviews 2/2014

01.03.2014

Could interferon-gamma be a therapeutic target for treating heart failure?

verfasst von: Scott P. Levick, Paul H. Goldspink

Erschienen in: Heart Failure Reviews | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The cytokine interferon-gamma (IFN-γ) is the only known member of the type II family of interferons, and as such, binds to its own distinct receptor. It is important in host defense against infection, as well as adaptive immune responses. While a wide array of cytokines are known to be involved in adverse remodeling of the heart and the progression to heart failure, the role of IFN-γ is unclear. Recent evidence from clinical studies, animal models of myocarditis and hypertension, as well as isolated cell studies, provide conflicting data as to whether IFN-γ is pathological or protective in the heart. Thus, it is important to highlight these discrepant findings so that areas of future investigation can be identified to more clearly determine the precise role of IFN-γ in the heart. Accordingly, this review will (1) discuss the source of IFN-γ in the diseased heart; (2) summarize the data from animal studies; (3) discuss the effects of IFN-γ on isolated cardiac fibroblasts and cardiomyocytes; (4) identify signaling mechanisms that may be invoked by IFN-γ in the heart; and (5) present the clinical evidence supporting a role for IFN-γ in heart failure.
Literatur
1.
Zurück zum Zitat Levine B, Kalman J, Mayer L, Fillit HM, Packer M (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323:236–241PubMedCrossRef Levine B, Kalman J, Mayer L, Fillit HM, Packer M (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323:236–241PubMedCrossRef
2.
Zurück zum Zitat Oikonomou E, Tousoulis D, Siasos G, Zaromitidou M, Papavassiliou AG, Stefanadis C (2011) The role of inflammation in heart failure: new therapeutic approaches. Hellenic J Cardiol 52:30–40PubMed Oikonomou E, Tousoulis D, Siasos G, Zaromitidou M, Papavassiliou AG, Stefanadis C (2011) The role of inflammation in heart failure: new therapeutic approaches. Hellenic J Cardiol 52:30–40PubMed
3.
Zurück zum Zitat Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N (2010) Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev 15:543–562PubMedCrossRef Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N (2010) Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev 15:543–562PubMedCrossRef
4.
Zurück zum Zitat Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 107:3133–3140PubMedCrossRef Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 107:3133–3140PubMedCrossRef
5.
Zurück zum Zitat Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS et al (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation 109:1594–1602PubMedCrossRef Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS et al (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation 109:1594–1602PubMedCrossRef
6.
Zurück zum Zitat Hinglais N, Huedes D, Nicoletti A, Manset C, Laurent M, Bariety J et al (1994) Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab Invest 70:286–294PubMed Hinglais N, Huedes D, Nicoletti A, Manset C, Laurent M, Bariety J et al (1994) Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab Invest 70:286–294PubMed
7.
Zurück zum Zitat Kanzaki Y, Terasaki F, Okabe M, Hayashi T, Toko H, Shimomura H et al (2001) Myocardial inflammatory cell infiltrates in cases of dilated cardiomyopathy as a determinant of outcome following partial left ventriculectomy. Jpn Circ J 65:797–802PubMedCrossRef Kanzaki Y, Terasaki F, Okabe M, Hayashi T, Toko H, Shimomura H et al (2001) Myocardial inflammatory cell infiltrates in cases of dilated cardiomyopathy as a determinant of outcome following partial left ventriculectomy. Jpn Circ J 65:797–802PubMedCrossRef
8.
Zurück zum Zitat Maekawa Y, Anzai T, Yoshikawa T, Asakura Y, Takahashi T, Ishikawa S et al (2002) Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: a possible role for left ventricular remodeling. J Am Coll Cardiol 39:241–246PubMedCrossRef Maekawa Y, Anzai T, Yoshikawa T, Asakura Y, Takahashi T, Ishikawa S et al (2002) Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: a possible role for left ventricular remodeling. J Am Coll Cardiol 39:241–246PubMedCrossRef
10.
Zurück zum Zitat Bujak M, Dobaczewski M, Chatila K, Mendoza LH, Li N, Reddy A et al (2008) Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol 173:57–67PubMedCrossRef Bujak M, Dobaczewski M, Chatila K, Mendoza LH, Li N, Reddy A et al (2008) Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol 173:57–67PubMedCrossRef
11.
Zurück zum Zitat Hayashidani S, Tsutsui H, Shiomi T, Ikeuchi M, Matsusaka H, Suematsu N et al (2003) Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 108:2134–2140PubMedCrossRef Hayashidani S, Tsutsui H, Shiomi T, Ikeuchi M, Matsusaka H, Suematsu N et al (2003) Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 108:2134–2140PubMedCrossRef
12.
Zurück zum Zitat Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K et al (2004) Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 43:739–745PubMedCrossRef Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K et al (2004) Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 43:739–745PubMedCrossRef
13.
Zurück zum Zitat Guedes PM, Veloso VM, Afonso LC, Caliari MV, Carneiro CM, Diniz LF et al (2009) Development of chronic cardiomyopathy in canine chagas disease correlates with high IFN-gamma, TNF-alpha, and low IL-10 production during the acute infection phase. Vet Immunol Immunopathol 130:43–52PubMedCrossRef Guedes PM, Veloso VM, Afonso LC, Caliari MV, Carneiro CM, Diniz LF et al (2009) Development of chronic cardiomyopathy in canine chagas disease correlates with high IFN-gamma, TNF-alpha, and low IL-10 production during the acute infection phase. Vet Immunol Immunopathol 130:43–52PubMedCrossRef
14.
Zurück zum Zitat Cheng X, Ding Y, Xia C, Tang T, Yu X, Xie J et al (2009) Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure. J Card Fail 15:158–162PubMedCrossRef Cheng X, Ding Y, Xia C, Tang T, Yu X, Xie J et al (2009) Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure. J Card Fail 15:158–162PubMedCrossRef
15.
Zurück zum Zitat Levick SP, McLarty JL, Murray DB, Freeman RM, Carver WE, Brower GL (2009) Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertension 53:1041–1047PubMedCrossRef Levick SP, McLarty JL, Murray DB, Freeman RM, Carver WE, Brower GL (2009) Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertension 53:1041–1047PubMedCrossRef
16.
Zurück zum Zitat Han YL, Li YL, Jia LX, Cheng JZ, Qi YF, Zhang HJ et al (2012) Reciprocal interaction between macrophages and T cells stimulates IFN-gamma and MCP-1 production in Ang II-induced cardiac inflammation and fibrosis. PLoS ONE 7:e35506PubMedCentralPubMedCrossRef Han YL, Li YL, Jia LX, Cheng JZ, Qi YF, Zhang HJ et al (2012) Reciprocal interaction between macrophages and T cells stimulates IFN-gamma and MCP-1 production in Ang II-induced cardiac inflammation and fibrosis. PLoS ONE 7:e35506PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Yu Q, Watson RR, Marchalonis JJ, Larson DF (2005) A role for T lymphocytes in mediating cardiac diastolic function. Am J Physiol Heart Circ Physiol 289:H643–H651PubMedCrossRef Yu Q, Watson RR, Marchalonis JJ, Larson DF (2005) A role for T lymphocytes in mediating cardiac diastolic function. Am J Physiol Heart Circ Physiol 289:H643–H651PubMedCrossRef
18.
Zurück zum Zitat Reifenberg K, Lehr HA, Torzewski M, Steige G, Wiese E, Kupper I et al (2007) Interferon-gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice. Am J Pathol 171:463–472PubMedCrossRef Reifenberg K, Lehr HA, Torzewski M, Steige G, Wiese E, Kupper I et al (2007) Interferon-gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice. Am J Pathol 171:463–472PubMedCrossRef
19.
Zurück zum Zitat Garcia AG, Wilson RM, Heo J, Murthy NR, Baid S, Ouchi N et al (2012) Interferon-gamma ablation exacerbates myocardial hypertrophy in diastolic heart failure. Am J Physiol Heart Circ Physiol 303:H587–H596PubMedCrossRef Garcia AG, Wilson RM, Heo J, Murthy NR, Baid S, Ouchi N et al (2012) Interferon-gamma ablation exacerbates myocardial hypertrophy in diastolic heart failure. Am J Physiol Heart Circ Physiol 303:H587–H596PubMedCrossRef
20.
Zurück zum Zitat Peng H, Yang XP, Carretero OA, Nakagawa P, D’Ambrosio M, Leung P et al (2011) Angiotensin II-induced dilated cardiomyopathy in Balb/c but not C57BL/6 J mice. Exp Physiol 96:756–764PubMedCentralPubMedCrossRef Peng H, Yang XP, Carretero OA, Nakagawa P, D’Ambrosio M, Leung P et al (2011) Angiotensin II-induced dilated cardiomyopathy in Balb/c but not C57BL/6 J mice. Exp Physiol 96:756–764PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Yu Q, Horak K, Larson DF (2006) Role of T lymphocytes in hypertension-induced cardiac extracellular matrix remodeling. Hypertension 48:98–104PubMedCrossRef Yu Q, Horak K, Larson DF (2006) Role of T lymphocytes in hypertension-induced cardiac extracellular matrix remodeling. Hypertension 48:98–104PubMedCrossRef
22.
Zurück zum Zitat Jin H, Li W, Yang R, Ogasawara A, Lu H, Paoni NF (2005) Inhibitory effects of interferon-gamma on myocardial hypertrophy. Cytokine 31:405–414PubMedCrossRef Jin H, Li W, Yang R, Ogasawara A, Lu H, Paoni NF (2005) Inhibitory effects of interferon-gamma on myocardial hypertrophy. Cytokine 31:405–414PubMedCrossRef
23.
Zurück zum Zitat Borda E, Leiros CP, Sterin-Borda L, de Bracco MM (1991) Cholinergic response of isolated rat atria to recombinant rat interferon-gamma. J Neuroimmunol 32:53–59PubMedCrossRef Borda E, Leiros CP, Sterin-Borda L, de Bracco MM (1991) Cholinergic response of isolated rat atria to recombinant rat interferon-gamma. J Neuroimmunol 32:53–59PubMedCrossRef
24.
Zurück zum Zitat Machado FS, Souto JT, Rossi MA, Esper L, Tanowitz HB, Aliberti J et al (2008) Nitric oxide synthase-2 modulates chemokine production by Trypanosoma cruzi-infected cardiac myocytes. Microbes Infect 10:1558–1566PubMedCentralPubMedCrossRef Machado FS, Souto JT, Rossi MA, Esper L, Tanowitz HB, Aliberti J et al (2008) Nitric oxide synthase-2 modulates chemokine production by Trypanosoma cruzi-infected cardiac myocytes. Microbes Infect 10:1558–1566PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Cunha-Neto E, Dzau VJ, Allen PD, Stamatiou D, Benvenutti L, Higuchi ML et al (2005) Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in chagas’ disease cardiomyopathy. Am J Pathol 167:305–313PubMedCrossRef Cunha-Neto E, Dzau VJ, Allen PD, Stamatiou D, Benvenutti L, Higuchi ML et al (2005) Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in chagas’ disease cardiomyopathy. Am J Pathol 167:305–313PubMedCrossRef
26.
Zurück zum Zitat Patten M, Kramer E, Bunemann J, Wenck C, Thoenes M, Wieland T et al (2001) Endotoxin and cytokines alter contractile protein expression in cardiac myocytes in vivo. Pflugers Arch 442:920–927PubMedCrossRef Patten M, Kramer E, Bunemann J, Wenck C, Thoenes M, Wieland T et al (2001) Endotoxin and cytokines alter contractile protein expression in cardiac myocytes in vivo. Pflugers Arch 442:920–927PubMedCrossRef
27.
Zurück zum Zitat Cosper PF, Harvey PA, Leinwand LA (2012) Interferon-gamma causes cardiac myocyte atrophy via selective degradation of myosin heavy chain in a model of chronic myocarditis. Am J Pathol 181:2038–2046PubMedCrossRef Cosper PF, Harvey PA, Leinwand LA (2012) Interferon-gamma causes cardiac myocyte atrophy via selective degradation of myosin heavy chain in a model of chronic myocarditis. Am J Pathol 181:2038–2046PubMedCrossRef
28.
Zurück zum Zitat Hellkvist J, Tufveson G, Gerdin B, Johnsson C (2002) Characterization of fibroblasts from rejecting tissue: the hyaluronan production is increased. Transplantation 74:1672–1677PubMedCrossRef Hellkvist J, Tufveson G, Gerdin B, Johnsson C (2002) Characterization of fibroblasts from rejecting tissue: the hyaluronan production is increased. Transplantation 74:1672–1677PubMedCrossRef
29.
Zurück zum Zitat Wang Z, Jiang B, Brecher P (2002) Selective inhibition of STAT3 phosphorylation by sodium salicylate in cardiac fibroblasts. Biochem Pharmacol 63:1197–1207PubMedCrossRef Wang Z, Jiang B, Brecher P (2002) Selective inhibition of STAT3 phosphorylation by sodium salicylate in cardiac fibroblasts. Biochem Pharmacol 63:1197–1207PubMedCrossRef
30.
Zurück zum Zitat Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75:163–189PubMedCrossRef Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75:163–189PubMedCrossRef
31.
Zurück zum Zitat Ramana CV, Gil MP, Schreiber RD, Stark GR (2002) Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol 23:96–101PubMedCrossRef Ramana CV, Gil MP, Schreiber RD, Stark GR (2002) Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol 23:96–101PubMedCrossRef
32.
Zurück zum Zitat Kurdi M, Booz GW (2009) JAK redux: a second look at the regulation and role of JAKs in the heart. Am J Physiol Heart Circ Physiol 297:H1545–H1556PubMedCrossRef Kurdi M, Booz GW (2009) JAK redux: a second look at the regulation and role of JAKs in the heart. Am J Physiol Heart Circ Physiol 297:H1545–H1556PubMedCrossRef
33.
Zurück zum Zitat Booz GW, Day JN, Baker KM (2002) Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol 34:1443–1453PubMedCrossRef Booz GW, Day JN, Baker KM (2002) Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol 34:1443–1453PubMedCrossRef
34.
Zurück zum Zitat Rohini A, Agrawal N, Koyani CN, Singh R (2010) Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res 61:269–280PubMedCrossRef Rohini A, Agrawal N, Koyani CN, Singh R (2010) Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res 61:269–280PubMedCrossRef
35.
Zurück zum Zitat Gough DJ, Sabapathy K, Ko EY, Arthur HA, Schreiber RD, Trapani JA et al (2007) A novel c-Jun-dependent signal transduction pathway necessary for the transcriptional activation of interferon gamma response genes. J Biol Chem 282:938–946PubMedCrossRef Gough DJ, Sabapathy K, Ko EY, Arthur HA, Schreiber RD, Trapani JA et al (2007) A novel c-Jun-dependent signal transduction pathway necessary for the transcriptional activation of interferon gamma response genes. J Biol Chem 282:938–946PubMedCrossRef
36.
Zurück zum Zitat McLarty JL, Melendez GC, Brower GL, Janicki JS, Levick SP (2011) Tryptase/protease-activated receptor 2 interactions induce selective mitogen-activated protein kinase signaling and collagen synthesis by cardiac fibroblasts. Hypertension 58:264–270PubMedCentralPubMedCrossRef McLarty JL, Melendez GC, Brower GL, Janicki JS, Levick SP (2011) Tryptase/protease-activated receptor 2 interactions induce selective mitogen-activated protein kinase signaling and collagen synthesis by cardiac fibroblasts. Hypertension 58:264–270PubMedCentralPubMedCrossRef
37.
Zurück zum Zitat Kehat I, Molkentin JD (2010) Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy. Ann N Y Acad Sci 1188:96–102PubMedCrossRef Kehat I, Molkentin JD (2010) Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy. Ann N Y Acad Sci 1188:96–102PubMedCrossRef
38.
Zurück zum Zitat Lin JJ, Jiang H, Fisher PB (1998) Melanoma differentiation associated gene-9, mda-9, is a human gamma interferon responsive gene. Gene 207:105–110PubMedCrossRef Lin JJ, Jiang H, Fisher PB (1998) Melanoma differentiation associated gene-9, mda-9, is a human gamma interferon responsive gene. Gene 207:105–110PubMedCrossRef
39.
Zurück zum Zitat Boukerche H, Su ZZ, Emdad L, Baril P, Balme B, Thomas L et al (2005) mda-9/Syntenin: a positive regulator of melanoma metastasis. Cancer Res 65:10901–10911PubMedCrossRef Boukerche H, Su ZZ, Emdad L, Baril P, Balme B, Thomas L et al (2005) mda-9/Syntenin: a positive regulator of melanoma metastasis. Cancer Res 65:10901–10911PubMedCrossRef
40.
Zurück zum Zitat Sarkar D, Boukerche H, Su ZZ, Fisher PB (2008) mda-9/Syntenin: more than just a simple adapter protein when it comes to cancer metastasis. Cancer Res 68:3087–3093PubMedCrossRef Sarkar D, Boukerche H, Su ZZ, Fisher PB (2008) mda-9/Syntenin: more than just a simple adapter protein when it comes to cancer metastasis. Cancer Res 68:3087–3093PubMedCrossRef
41.
Zurück zum Zitat Boukerche H, Aissaoui H, Prevost C, Hirbec H, Das SK, Su ZZ et al (2010) Src kinase activation is mandatory for MDA-9/syntenin-mediated activation of nuclear factor-kappaB. Oncogene 29:3054–3066PubMedCentralPubMedCrossRef Boukerche H, Aissaoui H, Prevost C, Hirbec H, Das SK, Su ZZ et al (2010) Src kinase activation is mandatory for MDA-9/syntenin-mediated activation of nuclear factor-kappaB. Oncogene 29:3054–3066PubMedCentralPubMedCrossRef
42.
Zurück zum Zitat Steinberg SF (2012) Cardiac actions of protein kinase C isoforms. Physiology (Bethesda) 27:130–139CrossRef Steinberg SF (2012) Cardiac actions of protein kinase C isoforms. Physiology (Bethesda) 27:130–139CrossRef
43.
Zurück zum Zitat Seo JY, Kim DY, Lee YS, Ro JY (2009) Cytokine production through PKC/p38 signaling pathways, not through JAK/STAT1 pathway, in mast cells stimulated with IFNgamma. Cytokine 46:51–60PubMedCrossRef Seo JY, Kim DY, Lee YS, Ro JY (2009) Cytokine production through PKC/p38 signaling pathways, not through JAK/STAT1 pathway, in mast cells stimulated with IFNgamma. Cytokine 46:51–60PubMedCrossRef
44.
Zurück zum Zitat Deb DK, Sassano A, Lekmine F, Majchrzak B, Verma A, Kambhampati S et al (2003) Activation of protein kinase C delta by IFN-gamma. J Immunol 171:267–273PubMed Deb DK, Sassano A, Lekmine F, Majchrzak B, Verma A, Kambhampati S et al (2003) Activation of protein kinase C delta by IFN-gamma. J Immunol 171:267–273PubMed
45.
Zurück zum Zitat Choudhury GG (2004) A linear signal transduction pathway involving phosphatidylinositol 3-kinase, protein kinase Cepsilon, and MAPK in mesangial cells regulates interferon-gamma-induced STAT1alpha transcriptional activation. J Biol Chem 279:27399–27409PubMedCrossRef Choudhury GG (2004) A linear signal transduction pathway involving phosphatidylinositol 3-kinase, protein kinase Cepsilon, and MAPK in mesangial cells regulates interferon-gamma-induced STAT1alpha transcriptional activation. J Biol Chem 279:27399–27409PubMedCrossRef
46.
Zurück zum Zitat Venkatesan BA, Mahimainathan L, Ghosh-Choudhury N, Gorin Y, Bhandari B, Valente AJ et al (2006) PI 3 kinase-dependent Akt kinase and PKCepsilon independently regulate interferon-gamma-induced STAT1alpha serine phosphorylation to induce monocyte chemotactic protein-1 expression. Cell Signal 18:508–518PubMedCrossRef Venkatesan BA, Mahimainathan L, Ghosh-Choudhury N, Gorin Y, Bhandari B, Valente AJ et al (2006) PI 3 kinase-dependent Akt kinase and PKCepsilon independently regulate interferon-gamma-induced STAT1alpha serine phosphorylation to induce monocyte chemotactic protein-1 expression. Cell Signal 18:508–518PubMedCrossRef
47.
Zurück zum Zitat Mazzi P, Donini M, Margotto D, Wientjes F, Dusi S (2004) IFN-gamma induces gp91phox expression in human monocytes via protein kinase C-dependent phosphorylation of PU.1. J Immunol 172:4941–4947PubMed Mazzi P, Donini M, Margotto D, Wientjes F, Dusi S (2004) IFN-gamma induces gp91phox expression in human monocytes via protein kinase C-dependent phosphorylation of PU.1. J Immunol 172:4941–4947PubMed
48.
Zurück zum Zitat Hardy PO, Diallo TO, Matte C, Descoteaux A (2009) Roles of phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase in the regulation of protein kinase C-alpha activation in interferon-gamma-stimulated macrophages. Immunology 128:e652–e660PubMedCrossRef Hardy PO, Diallo TO, Matte C, Descoteaux A (2009) Roles of phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase in the regulation of protein kinase C-alpha activation in interferon-gamma-stimulated macrophages. Immunology 128:e652–e660PubMedCrossRef
49.
Zurück zum Zitat Ivaska J, Bosca L, Parker PJ (2003) PKCepsilon is a permissive link in integrin-dependent IFN-gamma signalling that facilitates JAK phosphorylation of STAT1. Nat Cell Biol 5:363–369PubMedCrossRef Ivaska J, Bosca L, Parker PJ (2003) PKCepsilon is a permissive link in integrin-dependent IFN-gamma signalling that facilitates JAK phosphorylation of STAT1. Nat Cell Biol 5:363–369PubMedCrossRef
50.
Zurück zum Zitat Palaniyandi SS, Sun L, Ferreira JC, Mochly-Rosen D (2009) Protein kinase C in heart failure: a therapeutic target? Cardiovasc Res 82:229–239PubMedCrossRef Palaniyandi SS, Sun L, Ferreira JC, Mochly-Rosen D (2009) Protein kinase C in heart failure: a therapeutic target? Cardiovasc Res 82:229–239PubMedCrossRef
51.
Zurück zum Zitat Barnholt KE, Kota RS, Aung HH, Rutledge JC (2009) Adenosine blocks IFN-gamma-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation. J Immunol 183:6767–6777PubMedCentralPubMedCrossRef Barnholt KE, Kota RS, Aung HH, Rutledge JC (2009) Adenosine blocks IFN-gamma-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation. J Immunol 183:6767–6777PubMedCentralPubMedCrossRef
52.
Zurück zum Zitat Sikorski K, Czerwoniec A, Bujnicki JM, Wesoly J, Bluyssen HA (2011) STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNgamma, TLR4 and IL-6 in vascular disease. Cytokine Growth Factor Rev 22:211–219PubMedCrossRef Sikorski K, Czerwoniec A, Bujnicki JM, Wesoly J, Bluyssen HA (2011) STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNgamma, TLR4 and IL-6 in vascular disease. Cytokine Growth Factor Rev 22:211–219PubMedCrossRef
53.
Zurück zum Zitat Li N, Salter RC, Ramji DP (2011) Molecular mechanisms underlying the inhibition of IFN-gamma-induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRs. J Cell Biochem 112:675–683PubMedCrossRef Li N, Salter RC, Ramji DP (2011) Molecular mechanisms underlying the inhibition of IFN-gamma-induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRs. J Cell Biochem 112:675–683PubMedCrossRef
54.
Zurück zum Zitat Stephanou A (2002) Activated STAT-1 pathway in the myocardium as a novel therapeutic target in ischaemia/reperfusion injury. Eur Cytokine Netw 13:401–403PubMed Stephanou A (2002) Activated STAT-1 pathway in the myocardium as a novel therapeutic target in ischaemia/reperfusion injury. Eur Cytokine Netw 13:401–403PubMed
55.
Zurück zum Zitat Rocha Rodrigues DB, dos Reis MA, Romano A, Pereira SA, Teixeira VP, Tostes S Jr et al (2012) In situ expression of regulatory cytokines by heart inflammatory cells in Chagas’ disease patients with heart failure. Clin Dev Immunol 2012:361730PubMed Rocha Rodrigues DB, dos Reis MA, Romano A, Pereira SA, Teixeira VP, Tostes S Jr et al (2012) In situ expression of regulatory cytokines by heart inflammatory cells in Chagas’ disease patients with heart failure. Clin Dev Immunol 2012:361730PubMed
56.
Zurück zum Zitat Forster O, Hilfiker-Kleiner D, Ansari AA, Sundstrom JB, Libhaber E, Tshani W et al (2008) Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail 10:861–868PubMedCrossRef Forster O, Hilfiker-Kleiner D, Ansari AA, Sundstrom JB, Libhaber E, Tshani W et al (2008) Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail 10:861–868PubMedCrossRef
57.
Zurück zum Zitat Lio D, Scola L, Crivello A, Bonafe M, Franceschi C, Olivieri F et al (2002) Allele frequencies of +874T–> A single nucleotide polymorphism at the first intron of interferon-gamma gene in a group of Italian centenarians. Exp Gerontol 37:315–319PubMedCrossRef Lio D, Scola L, Crivello A, Bonafe M, Franceschi C, Olivieri F et al (2002) Allele frequencies of +874T–> A single nucleotide polymorphism at the first intron of interferon-gamma gene in a group of Italian centenarians. Exp Gerontol 37:315–319PubMedCrossRef
58.
Zurück zum Zitat Chong WP, Ip WK, Tso GH, Ng MW, Wong WH, Law HK et al (2006) The interferon gamma gene polymorphism +874A/T is associated with severe acute respiratory syndrome. BMC Infect Dis 6:82PubMedCentralPubMedCrossRef Chong WP, Ip WK, Tso GH, Ng MW, Wong WH, Law HK et al (2006) The interferon gamma gene polymorphism +874A/T is associated with severe acute respiratory syndrome. BMC Infect Dis 6:82PubMedCentralPubMedCrossRef
59.
Zurück zum Zitat Vallinoto AC, Graca ES, Araujo MS, Azevedo VN, Cayres-Vallinoto I, Machado LF et al (2010) IFNG +874T/A polymorphism and cytokine plasma levels are associated with susceptibility to Mycobacterium tuberculosis infection and clinical manifestation of tuberculosis. Hum Immunol 71:692–696PubMedCrossRef Vallinoto AC, Graca ES, Araujo MS, Azevedo VN, Cayres-Vallinoto I, Machado LF et al (2010) IFNG +874T/A polymorphism and cytokine plasma levels are associated with susceptibility to Mycobacterium tuberculosis infection and clinical manifestation of tuberculosis. Hum Immunol 71:692–696PubMedCrossRef
60.
Zurück zum Zitat Lutton CW, Gauntt CJ (1985) Ameliorating effect of IFN-beta and anti-IFN-beta on coxsackievirus B3-induced myocarditis in mice. J Interferon Res 5:137–146PubMedCrossRef Lutton CW, Gauntt CJ (1985) Ameliorating effect of IFN-beta and anti-IFN-beta on coxsackievirus B3-induced myocarditis in mice. J Interferon Res 5:137–146PubMedCrossRef
61.
Zurück zum Zitat Bartlett EJ, Lenzo JC, Sivamoorthy S, Mansfield JP, Cull VS, James CM (2004) Type I IFN-beta gene therapy suppresses cardiac CD8+ T-cell infiltration during autoimmune myocarditis. Immunol Cell Biol 82:119–126PubMedCrossRef Bartlett EJ, Lenzo JC, Sivamoorthy S, Mansfield JP, Cull VS, James CM (2004) Type I IFN-beta gene therapy suppresses cardiac CD8+ T-cell infiltration during autoimmune myocarditis. Immunol Cell Biol 82:119–126PubMedCrossRef
62.
Zurück zum Zitat Deonarain R, Cerullo D, Fuse K, Liu PP, Fish EN (2004) Protective role for interferon-beta in coxsackievirus B3 infection. Circulation 110:3540–3543PubMedCrossRef Deonarain R, Cerullo D, Fuse K, Liu PP, Fish EN (2004) Protective role for interferon-beta in coxsackievirus B3 infection. Circulation 110:3540–3543PubMedCrossRef
63.
Zurück zum Zitat Kuhl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M et al (2003) Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107:2793–2798PubMedCrossRef Kuhl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M et al (2003) Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107:2793–2798PubMedCrossRef
64.
Zurück zum Zitat Schultheiss HP, Kuhl U, Cooper LT (2011) The management of myocarditis. Eur Heart J 32:2616–2625PubMedCrossRef Schultheiss HP, Kuhl U, Cooper LT (2011) The management of myocarditis. Eur Heart J 32:2616–2625PubMedCrossRef
65.
Zurück zum Zitat Matsumori A, Tomioka N, Kawai C (1988) Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice. Am Heart J 115:1229–1232PubMedCrossRef Matsumori A, Tomioka N, Kawai C (1988) Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice. Am Heart J 115:1229–1232PubMedCrossRef
66.
Zurück zum Zitat Daliento L, Calabrese F, Tona F, Caforio AL, Tarsia G, Angelini A et al (2003) Successful treatment of enterovirus-induced myocarditis with interferon-alpha. J Heart Lung Transplant 22:214–217PubMedCrossRef Daliento L, Calabrese F, Tona F, Caforio AL, Tarsia G, Angelini A et al (2003) Successful treatment of enterovirus-induced myocarditis with interferon-alpha. J Heart Lung Transplant 22:214–217PubMedCrossRef
67.
Zurück zum Zitat Yamamoto N, Shibamori M, Ogura M, Seko Y, Kikuchi M (1998) Effects of intranasal administration of recombinant murine interferon-gamma on murine acute myocarditis caused by encephalomyocarditis virus. Circulation 97:1017–1023PubMedCrossRef Yamamoto N, Shibamori M, Ogura M, Seko Y, Kikuchi M (1998) Effects of intranasal administration of recombinant murine interferon-gamma on murine acute myocarditis caused by encephalomyocarditis virus. Circulation 97:1017–1023PubMedCrossRef
68.
Zurück zum Zitat Horwitz MS, La Cava A, Fine C, Rodriguez E, Ilic A, Sarvetnick N (2000) Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis. Nat Med 6:693–697PubMedCrossRef Horwitz MS, La Cava A, Fine C, Rodriguez E, Ilic A, Sarvetnick N (2000) Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis. Nat Med 6:693–697PubMedCrossRef
Metadaten
Titel
Could interferon-gamma be a therapeutic target for treating heart failure?
verfasst von
Scott P. Levick
Paul H. Goldspink
Publikationsdatum
01.03.2014
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 2/2014
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-013-9393-8

Weitere Artikel der Ausgabe 2/2014

Heart Failure Reviews 2/2014 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.